Prostate cancer is the most common cancer among men. The prospective discrimination of
aggressive and clinically insignificant tumors still poses a significant and, as yet, unsolved …

Prostate cancer is among the most common cancers. Although it has a relatively good
prognosis, 15 to 30% of men with prostate cancer experience a relapse after radical …

Background Molecular biomarkers that might help to distinguish between more aggressive
and clinically insignificant prostate cancers (PCa) are still urgently needed. Aberrant DNA …

PURPOSE: Radical prostatectomy is potentially curative in patients with clinically localized
prostate cancer. However, biochemical recurrence affects 15% to 30% of men who undergo …

PURPOSE: Approximately 35% of patients with prostate cancer who undergo radical
prostatectomy experience prostate specific antigen recurrence within 10 years of surgery …

Hypermethylation of the paired-like homeodomain transcription factor 2 (PITX2) gene is a
strong predictor of the risk of biochemical recurrence in patients with prostate cancer (PCa) …

Aim We investigated if methylation of candidate genes can be useful for predicting prostate
cancer (PCa) specific death. Patients & methods Methylation of PITX2, WNT5a, SPARC …

BACKGROUND: Hypermethylation of the PITX2 (paired-like homeodomain transcription
factor 2) gene promoter is strongly associated with recurrence after radical prostatectomy …

The insulin-like growth factor-I (IGF-IR) and androgen (AR) receptors are important players
in prostate cancer. Functional interactions between the IGF-I and androgen signaling …

Prostate cancer (PC) is the most commonly diagnosed neoplasm and the third most
common cause of cancer-related death amongst men in the Western world. PC is a clinically …